PMID- 34720154
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221003
IS  - 0018-5787 (Print)
IS  - 1945-1253 (Electronic)
IS  - 0018-5787 (Linking)
VI  - 56
IP  - 5
DP  - 2021 Oct
TI  - Intravenous Antibiotic Susceptibility for Urinary Tract Infection Prior to 
      Emergency Department Discharge.
PG  - 513-518
LID - 10.1177/0018578720925386 [doi]
AB  - BACKGROUND: Urinary tract infection (UTI) is a common infectious disease managed 
      in the emergency department (ED). Patients may be initially treated with an 
      intravenous (IV) antibiotic and subsequently discharged with an oral antibiotic 
      regimen. OBJECTIVE: The purpose of this study was to determine whether the 
      current Infectious Diseases Society of America guideline recommendation for an 
      initial dose of long-acting IV antibiotic for treatment of UTI when the 
      prevalence of fluoroquinolone resistance exceeds 10% improves the likelihood of 
      providing in vitro susceptibility to the isolated uropathogen. METHODS: This was 
      a retrospective study of patients in ED presenting between May 2009 and August 
      2018 who received treatment for UTI. The primary outcome was susceptibility of 
      uropathogen to the IV antibiotic administered. Secondary outcomes included 
      susceptibility to the oral antibiotic regimen prescribed at discharge, repeat 
      health care visit within 30 days related to UTI follow-up, adverse events (AEs) 
      associated with antibiotic use, and identification of risk factors associated 
      with pathogen resistance. RESULTS: A total of 255 patients were included for 
      analysis. Of these patients, 230 (90.2%) had pathogens susceptible to the 
      administered IV antibiotic. The oral regimen susceptibility was 81.6% with 29 
      patients returning for UTI follow-up and 4 patients reporting AEs related to 
      antibiotic use. Men and long-term care facility residents were more likely to 
      have resistant uropathogens. CONCLUSION: Administration of a long-acting IV 
      antibiotic for treatment of UTI prior to ED discharge is recommended when the 
      fluoroquinolone resistance rate exceeds 10% to improve in vitro susceptibility 
      coverage.
CI  - (c) The Author(s) 2020.
FAU - Rewitzer, Stacey
AU  - Rewitzer S
AUID- ORCID: 0000-0003-0858-3207
AD  - University of Iowa Hospitals & Clinics, Iowa City, USA.
AD  - University of Iowa Carver College of Medicine, Iowa City, USA.
AD  - University of Iowa College of Pharmacy, Iowa City, USA.
FAU - Montgomery, Josie
AU  - Montgomery J
AD  - University of Iowa Hospitals & Clinics, Iowa City, USA.
FAU - Zepeski, Anne
AU  - Zepeski A
AD  - University of Iowa Hospitals & Clinics, Iowa City, USA.
AD  - University of Iowa Carver College of Medicine, Iowa City, USA.
AD  - University of Iowa College of Pharmacy, Iowa City, USA.
FAU - Finer, Lexie
AU  - Finer L
AD  - University of Iowa College of Public Health, Iowa City, USA.
FAU - Faine, Brett A
AU  - Faine BA
AD  - University of Iowa Hospitals & Clinics, Iowa City, USA.
AD  - University of Iowa Carver College of Medicine, Iowa City, USA.
AD  - University of Iowa College of Pharmacy, Iowa City, USA.
LA  - eng
PT  - Journal Article
DEP - 20200531
PL  - United States
TA  - Hosp Pharm
JT  - Hospital pharmacy
JID - 0043175
PMC - PMC8554614
OTO - NOTNLM
OT  - antibiotic resistance
OT  - antibiotic therapy
OT  - emergency medicine
OT  - fluoroquinolones
OT  - urinary tract infection
COIS- Declaration of Conflicting Interests: The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2021/11/02 06:00
MHDA- 2021/11/02 06:01
PMCR- 2022/10/01
CRDT- 2021/11/01 08:50
PHST- 2021/11/01 08:50 [entrez]
PHST- 2021/11/02 06:00 [pubmed]
PHST- 2021/11/02 06:01 [medline]
PHST- 2022/10/01 00:00 [pmc-release]
AID - 10.1177_0018578720925386 [pii]
AID - 10.1177/0018578720925386 [doi]
PST - ppublish
SO  - Hosp Pharm. 2021 Oct;56(5):513-518. doi: 10.1177/0018578720925386. Epub 2020 May 
      31.